{"id":"https://openalex.org/W3201047607","doi":"https://doi.org/10.1002/acr2.11347","title":"Real\u2010World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study","display_name":"Real\u2010World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study","publication_year":2021,"publication_date":"2021-09-22","ids":{"openalex":"https://openalex.org/W3201047607","doi":"https://doi.org/10.1002/acr2.11347","mag":"3201047607","pmid":"https://pubmed.ncbi.nlm.nih.gov/34550647","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8672175"},"language":"en","primary_location":{"id":"doi:10.1002/acr2.11347","doi":"https://doi.org/10.1002/acr2.11347","is_oa":true,"landing_page_url":"https://doi.org/10.1002/acr2.11347","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acr2.11347","source":{"id":"https://openalex.org/S4210182786","display_name":"ACR Open Rheumatology","issn_l":"2578-5745","issn":["2578-5745"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-4"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACR Open Rheumatology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acr2.11347","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060348893","display_name":"Mwangi J. Murage","orcid":"https://orcid.org/0000-0003-2769-3188","observed_orcids":["https://orcid.org/0000-0003-2769-3188"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mwangi J. Murage","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004569020","display_name":"Nicole Princic","orcid":"https://orcid.org/0000-0003-3127-4365","observed_orcids":["https://orcid.org/0000-0003-3127-4365"]},"institutions":[{"id":"https://openalex.org/I1341412227","display_name":"IBM (United States)","ror":"https://ror.org/05hh8d621","country_code":"US","type":"company","lineage":["https://openalex.org/I1341412227"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Nicole Princic","raw_affiliation_strings":["IBM Watson Health, Cambridge, Massachusetts"],"raw_orcid":"https://orcid.org/0000-0003-3127-4365","affiliations":[{"raw_affiliation_string":"IBM Watson Health, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I1341412227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032700223","display_name":"Julie Park","orcid":"https://orcid.org/0000-0002-7755-4242","observed_orcids":["https://orcid.org/0000-0002-7755-4242"]},"institutions":[{"id":"https://openalex.org/I1341412227","display_name":"IBM (United States)","ror":"https://ror.org/05hh8d621","country_code":"US","type":"company","lineage":["https://openalex.org/I1341412227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julie Park","raw_affiliation_strings":["IBM Watson Health, Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IBM Watson Health, Cambridge, Massachusetts","institution_ids":["https://openalex.org/I1341412227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016030948","display_name":"William N. Malatestinic","orcid":"https://orcid.org/0000-0002-0830-6157","observed_orcids":["https://orcid.org/0000-0002-0830-6157"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Malatestinic","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057319160","display_name":"Baojin Zhu","orcid":"https://orcid.org/0000-0003-4462-1856","observed_orcids":["https://orcid.org/0000-0003-4462-1856"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Baojin Zhu","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086460024","display_name":"Bilal Atiya","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bilal Atiya","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110795734","display_name":"Scott A. Kern","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott A. Kern","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112862914","display_name":"Keri Brooke Stenger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Keri B. Stenger","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018869382","display_name":"Aubrey Trevelin Sprabery","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aubrey Trevelin Sprabery","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5014427334","display_name":"Alexis Ogdie","orcid":"https://orcid.org/0000-0002-4639-0775","observed_orcids":["https://orcid.org/0000-0002-4639-0775"]},"institutions":[{"id":"https://openalex.org/I2799810409","display_name":"Hospital of the University of Pennsylvania","ror":"https://ror.org/02917wp91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799810409","https://openalex.org/I4210143392"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexis Ogdie","raw_affiliation_strings":["Hospital of the University of Pennsylvania, Philadelphia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital of the University of Pennsylvania, Philadelphia","institution_ids":["https://openalex.org/I2799810409"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5004569020"],"corresponding_institution_ids":["https://openalex.org/I1341412227"],"apc_list":{"value":2700,"currency":"USD","value_usd":2700},"apc_paid":{"value":2700,"currency":"USD","value_usd":2700},"fwci":1.3164,"has_fulltext":true,"cited_by_count":11,"citation_normalized_percentile":{"value":0.78880794,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":97},"biblio":{"volume":"3","issue":"12","first_page":"879","last_page":"887"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.004699999932199717,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/psoriatic-arthritis","display_name":"psoriatic arthritis","score":1.0},{"id":"https://openalex.org/keywords/ixekizumab","display_name":"ixekizumab","score":1.0},{"id":"https://openalex.org/keywords/treatment-patterns","display_name":"treatment patterns","score":0.8119999766349792},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.8610000014305115},{"id":"https://openalex.org/keywords/medication-persistence","display_name":"treatment persistence","score":0.6990000009536743},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.7770000100135803},{"id":"https://openalex.org/keywords/biologic-switching","display_name":"biologic switching","score":0.7279999852180481},{"id":"https://openalex.org/keywords/dosing-patterns","display_name":"dosing patterns","score":0.8560000061988831},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.8569999933242798},{"id":"https://openalex.org/keywords/psoriasis-comorbidities","display_name":"psoriasis comorbidities","score":0.7770000100135803},{"id":"https://openalex.org/keywords/out-of-pocket-costs","display_name":"out-of-pocket costs","score":0.765999972820282}],"concepts":[{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.9066550731658936},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8929687142372131},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.7911360859870911},{"id":"https://openalex.org/C2779745271","wikidata":"https://www.wikidata.org/wiki/Q13574436","display_name":"Ixekizumab","level":5,"score":0.7886636257171631},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6019370555877686},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.5636085271835327},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.5003371238708496},{"id":"https://openalex.org/C3020604521","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Plaque psoriasis","level":3,"score":0.47142237424850464},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.45142996311187744},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4297488331794739},{"id":"https://openalex.org/C2779786854","wikidata":"https://www.wikidata.org/wiki/Q7444755","display_name":"Secukinumab","level":4,"score":0.38826802372932434},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.3452844023704529},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.31252366304397583},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.08496454358100891},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.1002/acr2.11347","doi":"https://doi.org/10.1002/acr2.11347","is_oa":true,"landing_page_url":"https://doi.org/10.1002/acr2.11347","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acr2.11347","source":{"id":"https://openalex.org/S4210182786","display_name":"ACR Open Rheumatology","issn_l":"2578-5745","issn":["2578-5745"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-4"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACR Open Rheumatology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8672175","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8672175","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACR Open Rheumatol","raw_type":"Text"},{"id":"pmid:34550647","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34550647","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACR open rheumatology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:aa2fd13e79474ac9b1c0b9d8c8cc1039","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/aa2fd13e79474ac9b1c0b9d8c8cc1039","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ACR Open Rheumatology, Vol 3, Iss 12, Pp 879-887 (2021)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1002/acr2.11347","doi":"https://doi.org/10.1002/acr2.11347","is_oa":true,"landing_page_url":"https://doi.org/10.1002/acr2.11347","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acr2.11347","source":{"id":"https://openalex.org/S4210182786","display_name":"ACR Open Rheumatology","issn_l":"2578-5745","issn":["2578-5745"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-4"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ACR Open Rheumatology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3201047607.pdf","grobid_xml":"https://content.openalex.org/works/W3201047607.grobid-xml"},"referenced_works_count":28,"referenced_works":["https://openalex.org/W1915713161","https://openalex.org/W1986491516","https://openalex.org/W2012579017","https://openalex.org/W2068616072","https://openalex.org/W2083180635","https://openalex.org/W2120407721","https://openalex.org/W2129168200","https://openalex.org/W2139788459","https://openalex.org/W2166575175","https://openalex.org/W2289328021","https://openalex.org/W2425231553","https://openalex.org/W2512436288","https://openalex.org/W2581492457","https://openalex.org/W2611448469","https://openalex.org/W2773179393","https://openalex.org/W2793492297","https://openalex.org/W2800970095","https://openalex.org/W2883072230","https://openalex.org/W2888686038","https://openalex.org/W2922555385","https://openalex.org/W2946069606","https://openalex.org/W2946295826","https://openalex.org/W2970140635","https://openalex.org/W2999008019","https://openalex.org/W3009701967","https://openalex.org/W3010766827","https://openalex.org/W3159598855","https://openalex.org/W4241915332"],"related_works":["https://openalex.org/W6901834638","https://openalex.org/W4311359321","https://openalex.org/W4315621321","https://openalex.org/W4385173213","https://openalex.org/W7130501898","https://openalex.org/W4313649029","https://openalex.org/W4400284922","https://openalex.org/W4297229131","https://openalex.org/W4223599202","https://openalex.org/W4210294848"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"describe":[2],"adherence,":[3],"persistence,":[4],"discontinuation,":[5],"restarting,":[6],"switching,":[7,93],"dosing,":[8],"and":[9,41,69,94,111,128,164,200,235,251],"health":[10,216],"care":[11,100,217],"costs":[12,101,118,206,223,237,252],"among":[13,253],"patients":[14,55,137,176,198,254],"with":[15,20,194,199,255,261],"psoriatic":[16],"arthritis":[17],"(PsA)":[18],"treated":[19],"ixekizumab":[21],"(IXE).":[22],"METHODS:":[23],"MarketScan":[24],"administrative":[25],"claims":[26],"databases":[27],"were":[28,97,102,112,177,192,224],"used":[29],"to":[30,167,188],"select":[31],"adults":[32],"(\u226518":[33],"years)":[34],"initiating":[35,257],"IXE":[36,50,186,205,222,258],"between":[37],"January":[38],"1,":[39],"2016,":[40],"June":[42],"30,":[43],"2019,":[44],"for":[45,119,126,197,212,229,264],"this":[46,244],"retrospective":[47],"study":[48],"(earliest":[49],"claim":[51],"=":[52,209],"index).":[53],"Eligible":[54],"had":[56,70,158],"one":[57],"or":[58],"more":[59],"PsA":[60,116,256],"diagnoses":[61],"during":[62,109],"the":[63,67,77,124,139,149,230],"12":[64,71],"months":[65,72],"preceding":[66],"index":[68],"of":[73,83,135,214,221],"follow-up":[74,110],"time":[75],"after":[76,114],"index.":[78],"Adherence":[79],"(measured":[80],"by":[81,123,238],"proportion":[82],"days":[84],"covered":[85],"[PDC])":[86],"persistence":[87],"(<60-day":[88],"gap),":[89,92],"discontinuation":[90],"(\u226590-day":[91],"dosing":[95],"patterns":[96,250],"reported.":[98],"Health":[99],"reported":[103,122],"per":[104,106],"patient":[105,225],"month":[107],"(PPPM)":[108],"assessed":[113],"adjusting":[115],"treatment":[117,249],"discount":[120],"rates":[121],"Institute":[125],"Clinical":[127],"Economic":[129],"Review":[130],"(ICER).":[131],"RESULTS:":[132],"A":[133],"total":[134],"496":[136],"met":[138],"selection":[140],"criteria":[141],"(mean":[142],"age,":[143],"51.1":[144],"years;":[145],"50.4%":[146],"female).":[147],"Over":[148],"12-month":[150],"follow-up,":[151],"52.8%":[152],"remained":[153],"persistent,":[154],"38.7%":[155],"discontinued,":[156],"13.5%":[157],"no":[159],"other":[160,265],"treatment,":[161],"4.6%":[162],"restarted,":[163],"20.6%":[165],"switched":[166],"a":[168],"new":[169],"biologic/traditional":[170],"synthetic":[171],"disease-modifying":[172],"antirheumatic":[173],"drug.":[174],"70.6%of":[175],"identified":[178],"as":[179],"highly":[180],"adherent":[181],"(i.e.":[182],"PDC":[183],">":[184],"0.80)to":[185],"prior":[187,262],"discontinuation.":[189],"Dose":[190],"values":[191],"consistent":[193,260],"prescribing":[195],"information":[196],"without":[201],"comorbid":[202],"psoriasis.":[203],"Although":[204],"($5233":[207],"[SD":[208],"$2497])":[210],"accounted":[211],"85.6%":[213],"PsA-related":[215,236],"costs,":[218],"only":[219],"3.5%":[220],"out-of-pocket":[226],"expenses.":[227],"Adjusting":[228],"ICER":[231],"discounts":[232],"decreased":[233],"all-cause":[234],"$2509":[239],"PPPM.":[240],"CONCLUSION:":[241],"Results":[242],"from":[243],"real-world":[245],"analysis":[246],"suggest":[247],"that":[248],"are":[259],"literature":[263],"biologics.":[266]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2021-09-27T00:00:00"}